With Its Hypertension Franchise in Crisis, Novartis Restructures
By
Michael Goodman / Email the Author / “The Pink Sheet” DAILY Jan. 13, 2012
Word Count: 925 / Article # 14120113006
Executive Summary
Novartis announced Jan. 13 the elimination of nearly 2,000 positions in its U.S. General Medicines business in the wake of the termination of a key clinical study of Tekturna and in anticipation of the expiration of Diovan’s U.S. patent later this year.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.